As the immunobiology of RB becomes clearer, and immune modulation strategies such as checkpoint blockade, ACT, CDK4/6 inhibition, anti-VEGF therapy, oncolytic virotherapy, and vaccination continue to evolve, these immunotherapeutic advances offer a compelling framework for improved RB management and expanded treatment paradigms (98). Here, CDK4 is linked to retinoblastoma.